Subgroup analysis by PD-L1 CPS did not inform in the CheckMate 649 trial, leaving the clinical efficacy of immunochemotherapy in low PD-L1-expressing G/GEJ adenocarcinoma unclear. The gene discussed is CD274; the disease is gastroesophageal junction adenocarcinoma.